Deep cardiac phenotyping by cardiovascular magnetic resonance reveals subclinical focal and diffuse myocardial injury in patients with psoriasis (PSOR-COR study).
Cardiovascular disease
Cardiovascular magnetic resonance
Fibrosis
Inflammation
Psoriasis
Tissue characterization
Journal
Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123
Informations de publication
Date de publication:
16 May 2024
16 May 2024
Historique:
received:
15
11
2023
accepted:
30
04
2024
medline:
16
5
2024
pubmed:
16
5
2024
entrez:
16
5
2024
Statut:
aheadofprint
Résumé
Psoriasis vulgaris (PV) is a chronic inflammatory disorder frequently associated with cardiovascular disease (CVD). This study aims to provide a prospective tissue characterization in patients with PV without major CVD using cardiovascular magnetic resonance (CMR). Patients with PV underwent laboratory assessment, a 12-lead and 24-h ECG, and a CMR exam at a 1.5-T scanner. Scan protocol included assessment of left (LV) and right (RV) ventricular function and strain analysis, native and post-contrast T1 mapping, T2 mapping and late gadolinium enhancement (LGE). In total, 60 PV patients (median(IQR) age in years: 50.0 (36.0-60.8); 34 men (56.7%)) were recruited and compared to 40 healthy volunteers (age in years: 49.5 (37.3-57.8); 21 men (53.0%)). No differences were found regarding LV and RV function (p = 0.78 and p = 0.75). Global radial and circumferential strains were lower in patients (p < 0.001 and p < 0.001, respectively). PV had higher global T1 times (1001 (982-1026) ms vs. 991 (968-1005) ms; p = 0.01) and lower global T2 times (48 (47-49) ms vs. 50 (48-51) ms; p < 0.001); however, all values were within local reference ranges. Focal non-ischemic fibrosis was observed in 17 (28.3%) PV patients. Deep cardiac phenotyping by CMR revealed subclinical myocardial injury in patients with PV without major CVD, despite preserved LV and RV function. Diffuse and focal fibrosis might be the first detectable signs of adverse tissue remodeling leading to reduced circumferential and radial myocardial deformation. In the background of local and systemic immunomodulatory therapy, no signs of myocardial inflammation were detected. The exact impact of immunomodulatory therapies on the myocardium needs to be addressed in future studies. ISRCTN71534700.
Sections du résumé
BACKGROUND
BACKGROUND
Psoriasis vulgaris (PV) is a chronic inflammatory disorder frequently associated with cardiovascular disease (CVD). This study aims to provide a prospective tissue characterization in patients with PV without major CVD using cardiovascular magnetic resonance (CMR).
METHODS
METHODS
Patients with PV underwent laboratory assessment, a 12-lead and 24-h ECG, and a CMR exam at a 1.5-T scanner. Scan protocol included assessment of left (LV) and right (RV) ventricular function and strain analysis, native and post-contrast T1 mapping, T2 mapping and late gadolinium enhancement (LGE).
RESULTS
RESULTS
In total, 60 PV patients (median(IQR) age in years: 50.0 (36.0-60.8); 34 men (56.7%)) were recruited and compared to 40 healthy volunteers (age in years: 49.5 (37.3-57.8); 21 men (53.0%)). No differences were found regarding LV and RV function (p = 0.78 and p = 0.75). Global radial and circumferential strains were lower in patients (p < 0.001 and p < 0.001, respectively). PV had higher global T1 times (1001 (982-1026) ms vs. 991 (968-1005) ms; p = 0.01) and lower global T2 times (48 (47-49) ms vs. 50 (48-51) ms; p < 0.001); however, all values were within local reference ranges. Focal non-ischemic fibrosis was observed in 17 (28.3%) PV patients.
CONCLUSION
CONCLUSIONS
Deep cardiac phenotyping by CMR revealed subclinical myocardial injury in patients with PV without major CVD, despite preserved LV and RV function. Diffuse and focal fibrosis might be the first detectable signs of adverse tissue remodeling leading to reduced circumferential and radial myocardial deformation. In the background of local and systemic immunomodulatory therapy, no signs of myocardial inflammation were detected. The exact impact of immunomodulatory therapies on the myocardium needs to be addressed in future studies.
STUDY REGISTRATION
BACKGROUND
ISRCTN71534700.
Identifiants
pubmed: 38753001
doi: 10.1007/s00392-024-02456-9
pii: 10.1007/s00392-024-02456-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : HORIZON EUROPE Framework Programme
ID : 18HLT05 QUIERO
Organisme : Charité - Universitätsmedizin Berlin
ID : Charite
Informations de copyright
© 2024. The Author(s).
Références
Boehncke WH, Schon MP (2015) Psoriasis. Lancet 386:983–994. https://doi.org/10.1016/S0140-6736(14)61909-7
doi: 10.1016/S0140-6736(14)61909-7
pubmed: 26025581
Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN (2021) Psoriasis. Lancet Lond Engl 397:1301–1315. https://doi.org/10.1016/S0140-6736(20)32549-6
doi: 10.1016/S0140-6736(20)32549-6
Armstrong AW, Mehta MD, Schupp CW et al (2021) Psoriasis prevalence in adults in the United States. JAMA Dermatol 157:940–946. https://doi.org/10.1001/jamadermatol.2021.2007
doi: 10.1001/jamadermatol.2021.2007
pubmed: 34190957
Ghoreschi K, Balato A, Enerbäck C, Sabat R (2021) Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet Lond Engl 397:754–766. https://doi.org/10.1016/S0140-6736(21)00184-7
doi: 10.1016/S0140-6736(21)00184-7
Armstrong AW, Read C (2020) Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA 323:1945–1960. https://doi.org/10.1001/jama.2020.4006
doi: 10.1001/jama.2020.4006
pubmed: 32427307
Masson W, Lobo M, Molinero G (2020) Psoriasis and cardiovascular risk: a comprehensive review. Adv Ther 37:2017–2033. https://doi.org/10.1007/s12325-020-01346-6
doi: 10.1007/s12325-020-01346-6
pubmed: 32314303
pmcid: 7467489
Ahlehoff O, Gislason GH, Charlot M et al (2011) Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 270:147–157. https://doi.org/10.1111/j.1365-2796.2010.02310.x
doi: 10.1111/j.1365-2796.2010.02310.x
pubmed: 21114692
Garshick MS, Ward NL, Krueger JG, Berger JS (2021) Cardiovascular risk in patients with psoriasis: JACC review topic of the week. J Am Coll Cardiol 77:1670–1680. https://doi.org/10.1016/j.jacc.2021.02.009
doi: 10.1016/j.jacc.2021.02.009
pubmed: 33795041
pmcid: 8168628
Snekvik I, Nilsen TIL, Romundstad PR, Saunes M (2019) Metabolic syndrome and risk of incident psoriasis: prospective data from the HUNT study, Norway. Br J Dermatol 180:94–99. https://doi.org/10.1111/bjd.16885
doi: 10.1111/bjd.16885
pubmed: 29904911
Qureshi AA, Choi HK, Setty AR, Curhan GC (2009) Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol 145:379–382. https://doi.org/10.1001/archdermatol.2009.48
doi: 10.1001/archdermatol.2009.48
pubmed: 19380659
pmcid: 2849106
Lonnberg AS, Skov L, Skytthe A et al (2016) Association of psoriasis with the risk for type 2 diabetes mellitus and obesity. JAMA Dermatol 152:761–767. https://doi.org/10.1001/jamadermatol.2015.6262
doi: 10.1001/jamadermatol.2015.6262
pubmed: 27120802
Armstrong AW, Lin SW, Chambers CJ et al (2011) Psoriasis and hypertension severity: results from a case-control study. PLoS One 6:e18227. https://doi.org/10.1371/journal.pone.0018227
doi: 10.1371/journal.pone.0018227
pubmed: 21479272
pmcid: 3066207
Kaye JA, Li L, Jick SS (2008) Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 159:895–902. https://doi.org/10.1111/j.1365-2133.2008.08707.x
doi: 10.1111/j.1365-2133.2008.08707.x
pubmed: 18616778
Kimball AB, Guerin A, Latremouille-Viau D et al (2010) Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis. Am J Med 123:350–357. https://doi.org/10.1016/j.amjmed.2009.08.022
doi: 10.1016/j.amjmed.2009.08.022
pubmed: 20362755
Kimball AB, Szapary P, Mrowietz U et al (2012) Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. J Am Acad Dermatol 67:76–85. https://doi.org/10.1016/j.jaad.2011.06.035
doi: 10.1016/j.jaad.2011.06.035
pubmed: 22018756
Dattilo G, Imbalzano E, Casale M et al (2018) Psoriasis and cardiovascular risk: correlation between psoriasis and cardiovascular functional indices. Angiology 69:31–37. https://doi.org/10.1177/0003319717699329
doi: 10.1177/0003319717699329
pubmed: 29212353
Bülbül Şen B, Ekiz Ö, Rifaioğlu EN et al (2016) Assessment of subclinical left ventricular dysfunction in patients with psoriasis by speckle tracking echocardiography: a Speckle Tracking Study. Int J Dermatol 55:158–164. https://doi.org/10.1111/ijd.12703
doi: 10.1111/ijd.12703
pubmed: 26104012
Zhou W, Teklu M, Bui V et al (2021) The relationship between systemic inflammation and increased left ventricular mass is partly mediated by noncalcified coronary artery disease burden in psoriasis. Am J Prev Cardiol 7:100211. https://doi.org/10.1016/j.ajpc.2021.100211
doi: 10.1016/j.ajpc.2021.100211
pubmed: 34611643
pmcid: 8387288
Kawel-Boehm N, Maceira A, Valsangiacomo-Buechel ER et al (2015) Normal values for cardiovascular magnetic resonance in adults and children. J Cardiovasc Magn Reson 17:29. https://doi.org/10.1186/s12968-015-0111-7
doi: 10.1186/s12968-015-0111-7
pubmed: 25928314
pmcid: 4403942
Messroghli DR, Moon JC, Ferreira VM et al (2017) Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). J Cardiovasc Magn Reson Off J Soc Cardiovasc Magn Reson 19:75. https://doi.org/10.1186/s12968-017-0389-8
doi: 10.1186/s12968-017-0389-8
Ferreira VM, Schulz-Menger J, Holmvang G et al (2018) Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol 72:3158–3176. https://doi.org/10.1016/j.jacc.2018.09.072
doi: 10.1016/j.jacc.2018.09.072
pubmed: 30545455
Fenski M, Grandy TH, Viezzer D et al (2022) Isotropic 3D compressed sensing (CS) based sequence is comparable to 2D-LGE in left ventricular scar quantification in different disease entities. Int J Cardiovasc Imaging. https://doi.org/10.1007/s10554-022-02571-6
doi: 10.1007/s10554-022-02571-6
pubmed: 35243574
pmcid: 10509092
Schmacht L, Traber J, Grieben U et al (2016) Cardiac involvement in myotonic dystrophy type 2 patients with preserved ejection fraction: detection by cardiovascular magnetic resonance. Circ Cardiovasc Imaging 9:e004615. https://doi.org/10.1161/CIRCIMAGING.115.004615
doi: 10.1161/CIRCIMAGING.115.004615
pubmed: 27363857
von Knobelsdorff-Brenkenhoff F, J S, S D, et al (2017) Detection and monitoring of acute myocarditis applying quantitative cardiovascular magnetic resonance. Circ Cardiovasc Imaging 10. https://doi.org/10.1161/CIRCIMAGING.116.005242
Birukov A, Wiesemann S, Golic M et al (2020) Myocardial evaluation of post-preeclamptic women by CMR: is early risk stratification possible? JACC Cardiovasc Imaging 13:1291–1293. https://doi.org/10.1016/j.jcmg.2020.01.005
doi: 10.1016/j.jcmg.2020.01.005
pubmed: 32061559
Blaszczyk E, Lim C, Kellman P et al (2021) Progressive myocardial injury in myotonic dystrophy type II and facioscapulohumeral muscular dystrophy 1: a cardiovascular magnetic resonance follow-up study. J Cardiovasc Magn Reson Off J Soc Cardiovasc Magn Reson 23:130. https://doi.org/10.1186/s12968-021-00812-6
doi: 10.1186/s12968-021-00812-6
Messroghli DR, Bainbridge GJ, Alfakih K et al (2005) Assessment of regional left ventricular function: accuracy and reproducibility of positioning standard short-axis sections in cardiac MR imaging. Radiology 235:229–236. https://doi.org/10.1148/radiol.2351040249
doi: 10.1148/radiol.2351040249
pubmed: 15731374
Gröschel J, Bhoyroo Y, Blaszczyk E et al (2022) Different impacts on the heart after COVID-19 infection and vaccination: insights from cardiovascular magnetic resonance. Front Cardiovasc Med 9:916922. https://doi.org/10.3389/fcvm.2022.916922
doi: 10.3389/fcvm.2022.916922
pubmed: 35911510
pmcid: 9329612
Langley RG, Ellis CN (2004) Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician’s Global Assessment. J Am Acad Dermatol 51:563–569. https://doi.org/10.1016/j.jaad.2004.04.012
doi: 10.1016/j.jaad.2004.04.012
pubmed: 15389191
Strober B, Ryan C, van de Kerkhof P et al (2020) Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol 82:117–122. https://doi.org/10.1016/j.jaad.2019.08.026
doi: 10.1016/j.jaad.2019.08.026
pubmed: 31425723
Schulz-Menger J, Bluemke DA, Bremerich J et al (2020) Standardized image interpretation and post-processing in cardiovascular magnetic resonance - 2020 update. J Cardiovasc Magn Reson 22:19. https://doi.org/10.1186/s12968-020-00610-6
doi: 10.1186/s12968-020-00610-6
pubmed: 32160925
pmcid: 7066763
Lim C, Blaszczyk E, Riazy L et al (2020) Quantification of myocardial strain assessed by cardiovascular magnetic resonance feature tracking in healthy subjects-influence of segmentation and analysis software. Eur Radiol. https://doi.org/10.1007/s00330-020-07539-5
doi: 10.1007/s00330-020-07539-5
pubmed: 33277669
pmcid: 8128822
Gargiulo P, Marsico F, Parente A et al (2014) Ischemic heart disease in systemic inflammatory diseases. An appraisal Int J Cardiol 170:286–290. https://doi.org/10.1016/j.ijcard.2013.11.048
doi: 10.1016/j.ijcard.2013.11.048
pubmed: 24331863
Cheng C-Y, Baritussio A, Giordani AS et al (2022) Myocarditis in systemic immune-mediated diseases: prevalence, characteristics and prognosis A systematic review. Autoimmun Rev 21:103037. https://doi.org/10.1016/j.autrev.2022.103037
doi: 10.1016/j.autrev.2022.103037
pubmed: 34995763
Goldenberg M, Reynolds M, Smart S et al (2020) A retrospective study of myocardial abnormalities detected on cardiac magnetic resonance imaging among patients with psoriasis compared to inflammatory skin disease controls. J Eur Acad Dermatol Venereol JEADV 34:e606–e608. https://doi.org/10.1111/jdv.16486
doi: 10.1111/jdv.16486
pubmed: 32299143
Ntusi NAB, Piechnik SK, Francis JM et al (2015) Diffuse myocardial fibrosis and inflammation in rheumatoid arthritis: insights from CMR T1 mapping. JACC Cardiovasc Imaging 8:526–536. https://doi.org/10.1016/j.jcmg.2014.12.025
doi: 10.1016/j.jcmg.2014.12.025
pubmed: 25890584
Guo Q, Wu L-M, Wang Z et al (2018) Early detection of silent myocardial impairment in drug-naive patients with new-onset systemic lupus erythematosus: a three-center prospective study. Arthritis Rheumatol Hoboken NJ 70:2014–2024. https://doi.org/10.1002/art.40671
doi: 10.1002/art.40671
Mavrogeni S, Sfikakis PP, Gialafos E et al (2014) Cardiac tissue characterization and the diagnostic value of cardiovascular magnetic resonance in systemic connective tissue diseases. Arthritis Care Res 66:104–112. https://doi.org/10.1002/acr.22181
doi: 10.1002/acr.22181
Puntmann VO, Isted A, Hinojar R et al (2017) T1 and T2 mapping in recognition of early cardiac involvement in systemic sarcoidosis. Radiology 285:63–72. https://doi.org/10.1148/radiol.2017162732
doi: 10.1148/radiol.2017162732
pubmed: 28448233
Zhang Y, Corona-Villalobos CP, Kiani AN et al (2015) Myocardial T2 mapping by cardiovascular magnetic resonance reveals subclinical myocardial inflammation in patients with systemic lupus erythematosus. Int J Cardiovasc Imaging 31:389–397. https://doi.org/10.1007/s10554-014-0560-3
doi: 10.1007/s10554-014-0560-3
pubmed: 25352245
Ntusi NAB, Francis JM, Sever E et al (2018) Anti-TNF modulation reduces myocardial inflammation and improves cardiovascular function in systemic rheumatic diseases. Int J Cardiol 270:253–259. https://doi.org/10.1016/j.ijcard.2018.06.099
doi: 10.1016/j.ijcard.2018.06.099
pubmed: 30017519
Makavos G, Ikonomidis I, Andreadou I et al (2020) Effects of interleukin 17A inhibition on myocardial deformation and vascular function in psoriasis. Can J Cardiol 36:100–111. https://doi.org/10.1016/j.cjca.2019.06.021
doi: 10.1016/j.cjca.2019.06.021
pubmed: 31606265
Hjuler KF, Bottcher M, Vestergaard C et al (2016) Association between changes in coronary artery disease progression and treatment with biologic agents for severe psoriasis. JAMA Dermatol 152:1114–1121. https://doi.org/10.1001/jamadermatol.2016.1984
doi: 10.1001/jamadermatol.2016.1984
pubmed: 27385305
Wu JJ, Joshi AA, Reddy SP et al (2018) Anti-inflammatory therapy with tumour necrosis factor inhibitors is associated with reduced risk of major adverse cardiovascular events in psoriasis. J Eur Acad Dermatol Venereol 32:1320–1326. https://doi.org/10.1111/jdv.14951
doi: 10.1111/jdv.14951
pubmed: 29573294
Heidenreich PA, Bozkurt B, Aguilar D et al (2022) 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation 145:e895–e1032. https://doi.org/10.1161/CIR.0000000000001063
doi: 10.1161/CIR.0000000000001063
pubmed: 35363499
Gorga E, Scodro M, Valentini F et al (2018) Echocardiographic evaluation of diastolic dysfunction in young and healthy patients with psoriasis: a case-control study. Monaldi Arch Chest Dis Arch Monaldi Mal Torace 88:934. https://doi.org/10.4081/monaldi.2018.934
doi: 10.4081/monaldi.2018.934
Pieske B, Tschöpe C, de Boer RA et al (2019) How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J 40:3297–3317. https://doi.org/10.1093/eurheartj/ehz641
doi: 10.1093/eurheartj/ehz641
pubmed: 31504452
Paulus WJ, Tschöpe C, Sanderson JE et al (2007) How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 28:2539–2550. https://doi.org/10.1093/eurheartj/ehm037
doi: 10.1093/eurheartj/ehm037
pubmed: 17428822
Zhao H, Huang R, Jiang M, et al (2023) Myocardial tissue-level characteristics of adults with metabolically healthy obesity. JACC Cardiovasc Imaging S1936–878X(23)00095–5. https://doi.org/10.1016/j.jcmg.2023.01.022
Piaserico S, Papadavid E, Cecere A et al (2023) Coronary microvascular dysfunction in asymptomatic patients with severe psoriasis. J Invest Dermatol 143:1929-1936.e2. https://doi.org/10.1016/j.jid.2023.02.037
doi: 10.1016/j.jid.2023.02.037
pubmed: 37739764
Piaserico S, Osto E, Famoso G et al (2019) Long-term prognostic value of coronary flow reserve in psoriasis patients. Atherosclerosis 289:57–63. https://doi.org/10.1016/j.atherosclerosis.2019.08.009
doi: 10.1016/j.atherosclerosis.2019.08.009
pubmed: 31476732
Rudolph A, Abdel-Aty H, Bohl S et al (2009) Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling. J Am Coll Cardiol 53:284–291. https://doi.org/10.1016/j.jacc.2008.08.064
doi: 10.1016/j.jacc.2008.08.064
pubmed: 19147047
Joy G, Artico J, Kurdi H et al (2021) Prospective case-control study of cardiovascular abnormalities 6 months following mild COVID-19 in healthcare workers. JACC Cardiovasc Imaging 14:2155–2166. https://doi.org/10.1016/j.jcmg.2021.04.011
doi: 10.1016/j.jcmg.2021.04.011
pubmed: 33975819
pmcid: 8105493
Williams MC, Kwiecinski J, Doris M et al (2020) Low-attenuation noncalcified plaque on coronary computed tomography angiography predicts myocardial infarction: results from the multicenter SCOT-HEART trial (Scottish Computed Tomography of the HEART). Circulation 141:1452–1462. https://doi.org/10.1161/CIRCULATIONAHA.119.044720
doi: 10.1161/CIRCULATIONAHA.119.044720
pubmed: 32174130
pmcid: 7195857
DISCHARGE Trial Group, Maurovich-Horvat P, Bosserdt M et al (2022) CT or invasive coronary angiography in stable chest pain. N Engl J Med 386:1591–1602. https://doi.org/10.1056/NEJMoa2200963
doi: 10.1056/NEJMoa2200963
Knuuti J, Wijns W, Saraste A et al (2020) 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 41:407–477. https://doi.org/10.1093/eurheartj/ehz425
doi: 10.1093/eurheartj/ehz425
pubmed: 31504439